|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology显示文摘 | J. Arends G. Bodoky F. Bozzetti K. Fearon M. Muscaritoli G. Selga M.A.E. van Bokhorst-de van der Schueren M. von Meyenfeldt G. Zürcher R. Fietkau E. Aulbert B. Frick M. Holm M. Kneba H.J. Mestrom A. Zander | 2006 | Clinical Nutrition2006，，2： | 6 |
| 2 | Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincrlstine, and prednlsone (CHOP) significantly improves the outcome for patients with advanced - stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low - Grade Lymphoma Study Group显示文摘 | Hiddemann W Kneba M Dreyling M | 2005 | Blood2005，106，12： | 1 |
| 3 | Frontline therapywith rituximab added to the combination of cyclophosphamide,doxorubicin, vincristine, and prednisone(CHOP) significantly improves the outcome for patientswith advanced-stage follicular lymphoma compared withtherapy with CHOP alone: results of a prospective randomizedstudy of the German Low -Grade LymphomaStudy Group显示文摘 | Hiddemann W Kneba M Dreyling M | 2005 | Blood2005，106，12： | 1 |
| 4 | Improvement of hammerhead ribozymes cleaving mdr-1 Mrna显示文摘 | Kneba M Hiddemann W | 1995 | Biol Chem Hoppe Seyler1995，376，5： | 1 |
| 5 | Frontline therapy with rituximab added to the combination of cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group显示文摘 | Hiddemann W Kneba M Dreyling M | 2005 | Blood2005，106，12： | 1 |
| 6 | Characterization of clone-specific rearrangement T-cell receptor gamma-chain genes in lymphomas and leukemias by the polymerase chain reaction and DNA sequencing显示文摘 | Bolz I Linke B | 1994 | Blood1994，84，2： | 1 |
| 7 | Frontline therapy with rituximab added to the combination of cyelophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group 显示文摘 | Hiddemann W Kneba M Dreyling M | 2005 | Blood2005，106，12： | 1 |
| 8 | IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-Ⅱ study of the German Low- Grade Lymphoma Study Group 显示文摘 | Feuring-Buske M Kneba M Unterhalt M | 2000 | Ann Hematol2000，79，9： | 1 |
| 9 | Risk-adaped treatment according to minimal residual disease in adult ALL显示文摘 | Gokbuget N Kneba M Raff T | 2002 | Best Pract Res Clin Haematol2002，15，4： | 1 |
| 10 | Acute lym- phoblastic leukemia: monitoring minimal residual disease as a therapeutic principle显示文摘 | Brtiggemann M GSkbuget N Kneba M | 2012 | Semin Oncol2012，39，1： | 1 |
| 11 | Adult patients with acute lymphoblastic leukemia and molecular failure display a poor and are candidates for stem cell transplantation and targeted therapies显示文摘 | G(o)kbuget N Kneba M Raff T | 2012 | {H}Blood2012，，： | 1 |
| 12 | High incidence of Epstein-Barr Virus genomes in Hodgkin' s disease显示文摘 | Herbst H Niedobitek G Kneba M | 1990 | Am J Pathol1990，137，： | 1 |
| 13 | Frontline therapy with fituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group 显示文摘 | Hiddemann W Kneba M Dreyling M | 2005 | Blood2005，106，： | 1 |
| 14 | Frontline thera- py with rituximab added to the combination of cyclophos- phamide, doxorubicin, vincristine, and prednisone (CHOP)significantly improves the outcome for patients with ad- vanced-stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group 显示文摘 | Hiddemann W Kneba M Drcyling M | 2005 | Blood2005，106，12： | 1 |
| 15 | Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle显示文摘 | Br L ggemann M G kbuget N Kneba M | 2012 | Semin Oncol2012，39，1： | 1 |
| 16 | Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin,vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicu- lar lymphoma compared with therapy with CHOP alone: re- sults of a prospective randomized study of the German Low- Grade Lymphoma Study Group 显示文摘 | Hiddemann W Kneba M Dreyling M etal | 2005 | Blood2005，106，12： | 1 |
| 17 | High incidence of Epstein-Barr Virus genomes in Hodgkin's disease显示文摘 | Herbst H Niedobitek G Kneba M | 1990 | Am J Pathol1990，137，1： | 1 |
| 18 | Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies显示文摘 | Gokbuget N Kneba M Raft T | 2012 | Blood2012，120，9： | 1 |
| 19 | The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma : Results of two prospective randomized studies of the German Low Grade Lymphoma Study (GLSG) 显示文摘 | Hiddemann W Fomtpointner R Kneba M | 2004 | Blood2004，104，： | 1 |
| 20 | Adult patients with acute lymphoblastic leukemia and molecularfailure display a poor prognosis and all candidates for stem cell transplantation and targeted therapies显示文摘 | Gokbuget N Kneba M Raft T et ah German Muhicenter Study Group for Adult Acute Lymphohlastic Leukemia | 2012 | Blond2012，120，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员